POLIVY  (Polatuzumab Vedotin)

Description

POLIVY  (Polatuzumab Vedotin)

Generic Name: Polatuzumab vedotin

Drug Class: CD79b-directed antibody-drug conjugate (ADC)

Indications:
Polivy is indicated for the treatment of adult patients with:
• Previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
• Relapsed or refractory DLBCL after at least two prior therapies, in combination with bendamustine and rituximab.

Mechanism of Action:
Polatuzumab vedotin is an antibody-drug conjugate that targets CD79b, a protein expressed on B cells. After binding to CD79b, the drug is internalized by the malignant B cell and releases monomethyl auristatin E (MMAE), a microtubule-disrupting agent that induces cell death.

Dosage and Administration:
The recommended dose is 1.8 mg/kg administered as an intravenous infusion every 21 days for 6 cycles. Premedication with an antihistamine and antipyretic is recommended before administration.

Common Adverse Reactions:
• Peripheral neuropathy
• Neutropenia
• Anemia
• Thrombocytopenia
• Fatigue
• Nausea
• Diarrhea
• Constipation
• Fever
• Decreased appetite

Warnings and Precautions:
• Peripheral neuropathy
• Infusion-related reactions
• Myelosuppression
• Serious and opportunistic infections
• Progressive multifocal leukoencephalopathy (PML)
• Tumor lysis syndrome
• Hepatotoxicity
• Embryo-fetal toxicity

Contraindications:
No specific contraindications are listed in the prescribing information; however, patients should be evaluated for severe infections and other risk factors before treatment.

Storage:
Store refrigerated at 2°C–8°C (36°F–46°F). Protect from light. Do not freeze or shake.

Monitoring Parameters:
• Complete blood counts (CBC)
• Liver function tests
• Signs of infection
• Neurological symptoms suggestive of peripheral neuropathy
• Infusion-related reactions

Pregnancy and Lactation:
Polivy may cause fetal harm. Effective contraception is recommended during treatment and for the specified period after the last dose. Breastfeeding is not recommended during treatment and for a period after therapy completion.